Skip to content

Community Promotion and Application of Wuqinxi combined with brief behavioral therapy for insomnia

Wuqinxi and other external treatment of Chinese Medicine combined with brief behavior therapy for insomnia

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100042845
Enrollment
Unknown
Registered
2021-01-30
Start date
2021-02-20
Completion date
Unknown
Last updated
2021-05-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

insomnia

Interventions

intervention group:Wuqinxi and other external therapies plus behavioral therapy
control group:Trazodone hydrochloride plus behavioral therapy

Sponsors

Jiangsu Vocational College of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. According to the DSM-V diagnostic criteria for insomnia, the TCM diagnostic criteria for insomnia and the syndrome type diagnostic criteria for insomnia in the diagnostic efficacy criteria for TCM diseases; 2. They have not used or stopped using antidepressants and other psychotropic drugs in the past month; 3. No serious physical disease; 4. Those who can cooperate with the treatment, voluntarily participate in the study and sign the informed consent; 5. Be able to complete the scale evaluation.

Exclusion criteria

Exclusion criteria: 1. Patients with severe mental illness or suicidal tendency; 2. Substance use disorders (including alcohol, tobacco, caffeine, sedatives, psychoactive drugs and other substance addiction or abuse); 3. History of epilepsy, mania, bipolar disorder and abnormal sleep; 4. Those who have practiced Wuqinxi regularly for a long time or are members of Wushu Association, Dance Association, aerobics Association, sanda association and Taekwondo Association; 5. Patients with severe cardiovascular disease, musculoskeletal system disease and other contraindications are not suitable for Wuqinxi exercise, or have contraindications of trazodone; 6. Liver and kidney dysfunction.

Design outcomes

Primary

MeasureTime frame
Insomnia Severity Index;Pittsburgh sleep quality index;

Secondary

MeasureTime frame
Self-Rating Anxiety Scale;Self-Rating Depression Scale;

Countries

China

Contacts

Public ContactZheng Yongliang

Jiangsu Vocational College of Medicine

12131@jsmc.edu.cn+86 15189305839

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 13, 2026